Nyumbani › Burkitt Lymphoma › Washington
Majaribio ya kliniki ya Burkitt Lymphoma katika jimbo la Washington
Masomo 11 ya Burkitt Lymphoma yanatafuta washiriki katika vituo vya jimbo la Washington.
Miji katika jimbo la Washington
Maandishi rasmi ya utafiti (Kiingereza)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
InaajiriHatua 2
366 Days – 46 Years · Jinsia zote · Imesasishwa 2 Okt 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
InaajiriHatua 2
365 Days · Jinsia zote · Imesasishwa 25 Sep 2026 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
InaajiriHatua 3
Umri 18 na zaidi · Jinsia zote · Imesasishwa 21 Sep 2026 · NCT07648264A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- na zaidi ya 1
InaajiriHatua 2
Umri 1 hadi 30 · Jinsia zote · Imesasishwa 1 Sep 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
InaajiriHatua 3
365 Days – 25 Years · Jinsia zote · Imesasishwa 25 Ago 2026 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Inaajiri
Umri 18 na zaidi · Jinsia zote · Imesasishwa 19 Ago 2026 · NCT06710418Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
InaajiriHatua 2Wajitolea wenye afya wanakaribishwa
6 Months · Jinsia zote · Imesasishwa 29 Mei 2026 · NCT04195633Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
InaajiriHatua 2
Umri 18 na zaidi · Jinsia zote · Imesasishwa 23 Apr 2026 · NCT07097363Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 13 Feb 2026 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Fred Hutchinson Cancer Research Center, Seattle
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 5 Nov 2025 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
InaajiriHatua 1
Umri 18 na zaidi · Jinsia zote · Imesasishwa 15 Nov 2024 · NCT06034275Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.